EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The intention of this trial is to evaluate safety and efficacy of a combination treatment of EndoTAG-1 with Gemcitabine versus Gemcitabine monotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MediGene
• Treatments: Gemcitabine; Paclitaxel; Pancreatin; Pancrelipase

Criteria

Inclusion Criteria:

• Inoperable adenocarcinoma of the pancreas

• Histologic or cytologic confirmation

• At least 18 years of age

Exclusion Criteria:

• Any chemotherapeutical treatment for pancreatic adenocarcinoma before enrollment

• Major surgery within 4 weeks prior to enrollment

• Major cardiovascular disease